Published preclinical and translational literature on Retatrutide (LY3437943) and adjacent triple-agonist sequences. Receptor pharmacology, in-vitro characterization, and the long-acting backbone modifications described across the source literature.
Retatrutide (LY3437943) is a single peptide with agonist activity at the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors. Published preclinical work characterizes its receptor selectivity profile, in-vitro signaling assays, and animal-model investigations of energy expenditure and glycemic regulation. The molecule also incorporates a fatty-acid acyl modification on a non-natural lysine, extending plasma half-life relative to native GLP-1.
The reading list below traces the compound from its discovery and proof-of-concept publications through subsequent dose-ranging investigations. The cited sources include the original synthesis and pharmacology paper, the first-in-human safety study, and ongoing work in adjacent indications such as metabolic dysfunction-associated steatotic liver disease.
Disclaimer · Citations are provided as reference material from the published research literature. Strata sells research compounds for laboratory use only and does not interpret, recommend, or extrapolate findings to human application.